Alphaviruses
WHAT WE DO
Alphavirus research services at VRS
At VRS, we work with a range of alphavirus systems to support antiviral discovery, vaccine and antibody research, assay development and fundamental studies of alphavirus biology.
Our current portfolio includes Semliki Forest virus, Sindbis virus and Ross River virus, as well as Chikungunya virus virus-like particles (VLPs). These systems provide complementary models for investigating alphavirus replication, neutralisation and host-virus interactions.
Alphaviruses used in research at VRS
At VRS, we work with a range of alphavirus systems to support antiviral discovery, vaccine and antibody research, assay development and fundamental studies of alphavirus biology.
Our current portfolio includes Semliki Forest virus, Sindbis virus and Ross River virus, as well as Chikungunya virus virus-like particles (VLPs). These systems provide complementary models for investigating alphavirus replication, neutralisation and host-virus interactions.
Semliki Forest virus
Semliki Forest virus (SFV) is a mosquito-borne alphavirus originally isolated in Uganda and is widely used as a model system for studying alphavirus replication and host-virus interactions. Although naturally associated with mosquito transmission, SFV has become an important experimental alphavirus because of its well-characterised replication cycle and broad utility in laboratory research.
SFV can be used in studies investigating viral replication, antiviral activity, virus-host interactions and the mechanisms underlying alphavirus entry and replication.
Sindbis virus
Sindbis virus is an enveloped mosquito-borne alphavirus with a broad geographical distribution. Human infection is generally associated with a febrile illness that may include rash and arthralgia, although neurological complications can occur.
Sindbis virus is also an established experimental model for alphavirus biology and can be used to investigate viral replication, antiviral activity, host-virus interactions and neutralising antibody responses.
Ross River virus
Ross River virus (RRV) is an Australian alphavirus and the causative agent of Ross River fever, the most common mosquito-borne disease reported in Australia. Infection can cause fever, rash and often prolonged joint pain and inflammation.
RRV provides a clinically relevant model for investigating alphavirus replication and antiviral activity, as well as the interactions between alphaviruses and host cells that contribute to inflammatory disease.
Chikungunya virus VLPs
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus best known for causing acute febrile illness accompanied by severe polyarthralgia, which can persist for months or even years in some individuals.
VRS also works with Chikungunya virus virus-like particles (VLPs). VLPs reproduce important structural and antigenic features of the virus without containing a complete viral genome, providing a non-replicating system for applications such as antibody and vaccine research, antigen characterisation and studies of virus entry and neutralisation.
Our assays
Alphavirus testing services
Virus quantification assays
TCID₅₀ assay and plaque assays are available for quantifying infectious Semliki Forest, Sindbis and Ross River viruses from biological samples and for evaluating the effect of antiviral compounds or other treatments on virus replication and release.
Bespoke infectivity and antigen-based quantification approaches can also be developed to meet project-specific requirements.
Antiviral and cytotoxicity assays
Antiviral and cytotoxicity assays are available for evaluating compounds against alphaviruses, including Semliki Forest virus, Sindbis virus and Ross River virus.
Assays can be configured according to the objective of the study, including assessment of antiviral activity, concentration-response relationships and compound-associated cytotoxicity.
Our antiviral and cytotoxicity assays are ISO 17025 accredited.
Neutralisation assays
Our microneutralisation assays measure the neutralising activity of antibodies, sera and other test articles against Chikungunya virus VLPs.
Depending on the study requirements, assays can be developed using infectious virus (Semliki, Sindbis, or Ross River) or VLPs, providing flexibility for antibody characterisation, vaccine research and evaluation of immune responses.
Our neutralisation assays are ISO 17025 accredited.
Bespoke studies
VRS also offers bespoke studies, including customised assay development, mechanism-of-action studies, virus characterisation and fundamental virology research.
Background
What are alphaviruses?
Alphaviruses are enveloped, positive-sense, single-stranded RNA viruses belonging to the genus Alphavirus within the family Togaviridae. The genus includes more than 30 recognised viruses, which can broadly be divided into mosquito-borne alphaviruses associated with human and animal disease and other alphaviruses with distinct ecological and geographical distributions. Important medically relevant alphaviruses include chikungunya virus, Ross River virus, Sindbis virus, Mayaro virus and several encephalitic alphaviruses.
Alphaviruses are transmitted primarily by mosquitoes and have complex transmission cycles involving both vertebrate hosts and arthropod vectors. Depending on the virus, humans may act as incidental hosts or, in some cases, contribute substantially to transmission. Alphavirus infections can cause a wide range of clinical manifestations, from relatively mild febrile illness to severe neurological disease. Chikungunya and Ross River viruses are particularly associated with fever, rash and debilitating arthralgia, whereas several other alphaviruses can cause encephalitis and other neurological complications.
Alphaviruses share a broadly conserved genome organisation. Their approximately 11–12 kb positive-sense RNA genome contains non-structural proteins at the 5′ end, which form the viral replication machinery, followed by structural proteins expressed from a subgenomic RNA. The structural region encodes the capsid protein and the envelope glycoproteins E1 and E2, together with associated small membrane proteins. E1 is primarily responsible for membrane fusion, while E2 plays an important role in receptor interaction and attachment and is a major target of neutralising antibodies.
Following attachment to susceptible cells, alphaviruses enter through receptor-mediated endocytosis. Acidification of the endosome triggers conformational changes in the viral envelope proteins, allowing E1-mediated fusion of the viral and endosomal membranes and release of the viral RNA genome into the cytoplasm. The incoming genomic RNA is translated to produce the non-structural proteins, which assemble into a replication complex associated with intracellular membranes. Viral RNA replication produces both genomic RNA and a shorter subgenomic RNA, the latter directing expression of the structural proteins. Virion assembly occurs at the plasma membrane, where nucleocapsids interact with the cytoplasmic domains of the envelope glycoproteins before budding from the cell.
The alphavirus replication cycle is therefore highly dependent on interactions between viral proteins and host-cell membranes. Following infection, substantial changes occur to cellular membrane architecture and intracellular trafficking, while innate immune responses are activated through recognition of viral RNA and replication intermediates. These host-virus interactions are important determinants of viral replication, tropism and pathogenicity and provide potential targets for antiviral intervention.
Frequently Asked Questions
Do you work with live alphaviruses?
Yes. We perform studies using live, replication-competent alphaviruses, including Semliki Forest virus, Sindbis virus and Ross River virus.
We also work with non-replicating Chikungunya virus VLPs where a virus-like particle system is more appropriate for the research application.
Why choose VRS for alphavirus studies?
VRS has extensive experience working with complex RNA viruses, including mosquito-borne alphaviruses, supporting pharmaceutical and biotechnology programmes from early discovery through to candidate characterisation.
Our expertise includes virus propagation, virus quantification, antiviral and neutralisation assays, and bespoke assay development using biologically relevant models.
We combine deep virology expertise with flexible assay development capabilities, enabling us to design robust workflows for challenging biological questions where standard approaches are not sufficient.
Can you adapt existing assays to our specific requirements?
Yes. All experimental work is carried out by our scientific team within our UK laboratories. We do not subcontract laboratory work to third parties.
Where a project requires specialist services outside our scope (for example, peptide synthesis or animal studies), we can coordinate with trusted collaborators while remaining your primary scientific contact throughout the project.
How can I find out more?
You can explore our related resources, including technical articles, case studies and virus-specific services, using the Learn More section above.
If you would like to discuss your project directly, please contact us using our contact form or email vrs@virologyresearchservices.com.
Subscribe